Trials
1 active
2 in total
Targets
—
None known yet
What this is
- How it works
- How it works isn't classified yet
- How it’s given
- “Subjects will be randomized to receive BB-101 or placebo, and expected 32 subjects for each arm.”In the company’s words, NCT06383013 on ClinicalTrials.gov
- Tested for
- Diabetic Foot Ulcer
- Main trialPhase 2
- “This is a randomized, double-blinded, vehicle-controlled, parallel, phase II study to evaluate the efficacy and safety of topical BB-101 for the treatment of diabetic lower leg and foot ulcer.”In the company’s words, NCT06383013 on ClinicalTrials.gov
Other drugs for Diabetic Foot Ulcer
- BIOxHEALApplied Biologics, LLC · Phase 3
- Amniotic Tissue AllograftBardia Anvar · Phase 3
- ENERGI-F703Energenesis Biomedical Co., Ltd. · Phase 3
- Xianglei Tangzu GaoOneness Biotech Co., Ltd. · Phase 2/3
- Nu-3 gelLakewood-Amedex Inc · Phase 2
- Antimicrobial Peptide PL-5 Topical SprayJiangsu ProteLight Pharmaceutical & Biotechnology Co., Ltd. · Phase 2
Coming up1
- 31 Dec 2027Phase 2 trial completes · ClinicalTrials.gov
Changes0
Last 90 daysNo changes yet. We started recording changes on 6 Nov 2026.
Trials2
| Trial | Phase | Completes | What it tests |
|---|---|---|---|
| Phase 2Recruiting | 31 Dec 2027 | BB-101 for the Treatment of Diabetic Lower Leg and Foot Ulcers | |
| Phase 1Completed | 1 Dec 2021 | BB-101 for Treatment of Diabetic Lower Leg and Foot Ulcers |
A trial in both registries shows both numbers.
About
- Sources
- ClinicalTrials.gov updated 19 Nov 2026 · EU trials register (CTIS) updated 19 Nov 2026 · openFDA updated 19 Nov 2026